Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, What is the potential impact of integrating reduced-chemotherapy and chemotherapy-free approaches into acute lymphoblastic leukemia (ALL) treatment strategies?

In this interview, Jabbour discusses the growing evidence supporting chemotherapy-reduced and chemotherapy-free treatment approaches in ALL. He highlights how advances in targeted therapies, including blinatumomab, inotuzumab ozogamicin, tyrosine kinase inhibitors, and CAR T-cell therapy, together with measurable residual disease-guided treatment strategies, are transforming the management of ALL. Drawing on recent clinical studies, he explores the potential to reduce chemotherapy intensity, minimize the need for allogeneic stem cell transplantation, and improve long-term outcomes across different ALL subtypes and patient populations.

This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

During the ALL Hub Steering Committee meeting in April 2026, Daniel DeAngelo led a discussion on the latest findings from the phase Ib/II FELIX trial (NCT04404660) investigating obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The discussion featured contributions from Ibrahim Aldoss, José María Ribera, André Baruchel, Wendy Stock, and Nicolas Boissel.

This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Claire Roddie, University College London Cancer Institute, London, UK. We asked, where does obecabtagene autoleucel (obe-cel) currently fit in the treatment algorithm for B-cell acute lymphoblastic leukemia (B-cell ALL), and how might this evolve?

In this interview, Roddie discusses the current regulatory approvals for obe-cel for the treatment of B-cell ALL and the key findings from the phase Ib/II FELIX trial. Roddie also outlines the evolving role of obe-cel in the treatment of ALL, including ongoing studies investigating its use earlier in the treatment paradigm, and concludes by highlighting the importance of developing biomarker assays to monitor patients following CAR T-cell infusion.

This educational resource is independently supported by Autolus. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Ibrahim Aldoss, City of Hope, Duarte, US. We asked, What are the recommendations for addressing challenges in implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?

In this interview, Aldoss discusses the challenges associated with implementing asparaginase-based regimens in AYA patients with ALL and shares recommendations to overcome them, which were recently established and published by a US consensus panel.

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub spoke with Luke Maese, University of Utah Huntsman Cancer Institute and Primary Children’s Hospital, Salt Lake City, US. We asked, What are the main barriers associated with implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with ALL.

In this interview, Maese discussed the main challenges faced when treating AYA patients with ALL and the difficulties associated with facilitating the implementation of asparaginase-based regimens to treat this patient population.

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

The ALL Hub was pleased to speak with Wendy Stock, the University of Chicago, US. We asked, What is the rationale for the use of pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?

In this interview, Stock reviews the clinical evidence and key considerations supporting this treatment approach in the AYA patient population.

This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the ALL Hub Steering Committee meeting in November 2025, key opinion leaders met to discuss strategies to prevent relapse post hematopoietic stem cell transplantation (HSCT) / cellular therapy in B-cell acute lymphoblastic leukemia (B-ALL). The meeting opened with a presentation by Ibrahim Aldoss and featured a discussion including Charles Mullighan, José María Ribera, Sabina Chiaretti, Andre Baruchel, Wendy Stock, Daniel DeAngelo, and Anita Rijneveld.

During his presentation, Aldoss highlighted that despite advances in multi-agent chemotherapy and novel immunotherapies allowing an increased number of patients to undergo allogeneic (allo) HSCT – a potentially curative approach in B-ALL – post-transplant relapse, as well as relapse following CAR T-cell therapy, remains a major cause of treatment failure. He discussed several studies exploring relapse-preventive measures post transplantation, including established strategies such as tyrosine kinase (TKI) maintenance in patients with Philadelphia-chromosome positive (Ph+) ALL, and newer strategies, such as the use of blinatumomab, inotuzumab ozogamicin, or prophylactic donor-derived CAR T-cell therapy, which have shown promising initial activity in patients with B-ALL. He also outlined the major considerations that influence the decision to initiate maintenance therapy after allo-HSCT or salvage therapy post-CAR T-cell therapy.

This educational resource is independently supported by Pfizer. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.

Hosted on Acast. See acast.com/privacy for more information.